{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:12:56Z","timestamp":1789506776047,"version":"build-2803163510"},"reference-count":101,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Temozolomide (TMZ) remains foundational in the management of adult-type diffuse gliomas in general, and glioblastoma specifically. However, its efficacy harbors an evolutionary trade-off. TMZ drives its cytotoxicity through generating O6-methylguanine lesions, especially active in MGMT-silenced, mismatch repair (MMR)-proficient tumors. By selecting for acquired MMR-deficient subclones, often via MSH6 inactivation, this process escalates into a hypermutator phenotype, generating thousands of de novo alterations. This is a hallmark of the mutational signature known as SBS11, characterized by C&gt;T transitions, which is associated with TMZ treatment. The hypermutator phenotype drives heterogeneity, therapeutic resistance, spatial diversification, and distant recurrence. Despite harboring a mutational burden comparable to melanoma and lung cancer, TMZ-induced hypermutation does not sensitize gliomas to immune checkpoint blockade. This resistance reflects the profoundly immunosuppressive brain microenvironment, impaired antigen presentation, marked transcriptional plasticity, and perhaps also the frequent use of corticosteroids. Emerging strategies aim to exploit vulnerabilities created by TMZ-mediated genomic instability, including PARP, ATR, WEE1, and AURKA inhibition; alternative alkylators; metabolic rewiring; and G-quadruplex stabilization. Notably, the real-time detection of evolving mutational signatures via CSF-based liquid biopsies may enable adaptive therapy before radiographic progression. By reframing TMZ as a potent evolutionary agent rather than a conventional chemotherapy, this review synthesizes recent mechanistic insights and translational opportunities to guide a next-generation, evolution-informed treatment paradigm for glioma.<\/jats:p>","DOI":"10.3390\/cells15010057","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:52:59Z","timestamp":1766994779000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-2307","authenticated-orcid":false,"given":"Adar","family":"Yaacov","sequence":"first","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Gillis","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber","family":"Salim","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Katz","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Asna","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-5953","authenticated-orcid":false,"given":"Iddo","family":"Paldor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"},{"name":"Neurosurgery Department, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-5719","authenticated-orcid":false,"given":"Albert","family":"Grinshpun","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/neuonc\/noac217","article-title":"Global Survival Trends for Brain Tumors, by Histology: Analysis of Individual Records for 556,237 Adults Diagnosed in 59 Countries during 2000-2014 (CONCORD-3)","volume":"25","author":"Girardi","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and Other Malignant Gliomas: A Clinical Review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae Insights: Central Nervous System Cancers, Version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_9","first-page":"CD007415","article-title":"Temozolomide for High Grade Glioma","volume":"2013","author":"Hart","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11060-025-04952-y","article-title":"Treatment Practices and Survival Outcomes for IDH-Wildtype Glioblastoma Patients According to MGMT Promoter Methylation Status: Insights from the U.S. National Cancer Database","volume":"172","author":"Pham","year":"2025","journal-title":"J. Neuro Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaoncol.2023.0990","article-title":"Association of MGMT Promoter Methylation with Survival in Low-Grade and Anaplastic Gliomas After Alkylating Chemotherapy","volume":"9","author":"Kinslow","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-Associated Hypermutation in Gliomas","volume":"20","author":"Choi","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal Molecular Trajectories of Diffuse Glioma in Adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2019.03.001","article-title":"A Compendium of Mutational Signatures of Environmental Agents","volume":"177","author":"Kucab","year":"2019","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The Repertoire of Mutational Signatures in Human Cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110676","DOI":"10.1016\/j.jbc.2025.110676","article-title":"Biochemical Reconstitution of Temozolomide-Induced Mutational Processes","volume":"301","author":"Sanyal","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1038\/s41467-025-59775-2","article-title":"Unraveling Mutagenic Processes Influencing the Tumor Mutational Patterns of Individuals with Constitutional Mismatch Repair Deficiency","volume":"16","author":"Weijers","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"zcad015","DOI":"10.1093\/narcan\/zcad015","article-title":"Molecular Origins of Mutational Spectra Produced by the Environmental Carcinogen N-Nitrosodimethylamine and SN1 Chemotherapeutic Agents","volume":"5","author":"Armijo","year":"2023","journal-title":"NAR Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and Therapeutic Implications of Hypermutation in Gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of Action, Repair and Resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113339","DOI":"10.1016\/j.celrep.2023.113339","article-title":"Targeting the Non-Coding Genome and Temozolomide Signature Enables CRISPR-Mediated Glioma Oncolysis","volume":"42","author":"Tan","year":"2023","journal-title":"Cell Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","article-title":"Temozolomide-Induced Hypermutation Is Associated with Distant Recurrence and Reduced Survival after High-Grade Transformation of Low-Grade IDH-Mutant Gliomas","volume":"23","author":"Yu","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2015.07.013","article-title":"Spatiotemporal Evolution of the Primary Glioblastoma Genome","volume":"28","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"abl9283","DOI":"10.1126\/science.abl9283","article-title":"Substitution Mutational Signatures in Whole-Genome-Sequenced Cancers in the UK Population","volume":"376","author":"Degasperi","year":"2022","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"gkae1122","DOI":"10.1093\/nar\/gkae1122","article-title":"Comprehensive Whole-Genome Sequencing Reveals Origins of Mutational Signatures Associated with Aging, Mismatch Repair Deficiency and Temozolomide Chemotherapy","volume":"53","author":"Hwang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chowdhury, T., Tesileanu, C.M.S., Kocakavuk, E., Johnson, K.C., Lee, J., Erson-Omay, Z., Heo, C., Aldape, K., Amin, S.B., and Anderson, K.J. (2025). Tumor-Initiating Genetics and Therapy Drive Divergent Molecular Evolution in IDH-Mutant Gliomas. bioRxiv.","DOI":"10.1101\/2025.07.11.664189"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","article-title":"A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy","volume":"66","author":"Hunter","year":"2006","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1158\/0008-5472.CAN-22-2036","article-title":"MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma","volume":"82","author":"Gan","year":"2022","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s40478-023-01669-9","article-title":"Genomic Characterization of IDH-Mutant Astrocytoma Progression to Grade 4 in the Treatment Setting","volume":"11","author":"Rautajoki","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40478-024-01889-7","article-title":"Homozygous CDKN2A\/B Deletions in Low- and High-Grade Glioma: A Meta-Analysis of Individual Patient Data and Predictive Values of P16 Immunohistochemistry Testing","volume":"12","author":"Noack","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor Heterogeneity in Human Glioblastoma Reflects Cancer Evolutionary Dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-024-01900-1","article-title":"Discontiguous Recurrences of IDH-Wildtype Glioblastoma Share a Common Origin with the Initial Tumor and Are Frequently Hypermutated","volume":"13","author":"McDonald","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking Tumour Evolution in Glioma through Liquid Biopsies of Cerebrospinal Fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s12967-025-06706-w","article-title":"Single-Cell and Spatial Transcriptome Analyses Reveal MAZ(+) NPC-like Clusters as Key Role Contributing to Glioma Recurrence and Drug Resistance","volume":"23","author":"Gu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41540-025-00493-2","article-title":"Network Analyses of Brain Tumor Multiomic Data Reveal Pharmacological Opportunities to Alter Cell State Transitions","volume":"11","author":"Bumbaca","year":"2025","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728222.2016.1151002","article-title":"mTOR Inhibition Decreases SOX2-SOX9 Mediated Glioma Stem Cell Activity and Temozolomide Resistance","volume":"20","author":"Aldaz","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41419-025-07617-w","article-title":"Temozolomide Promotes Glioblastoma Stemness Expression through Senescence-Associated Reprogramming via HIF1\u03b1\/HIF2\u03b1 Regulation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III Trial of Chemoradiotherapy with Temozolomide plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma with Methylated MGMT Promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy Combined with Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter: An International Randomized Phase III Trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"vdac076","DOI":"10.1093\/noajnl\/vdac076","article-title":"Detection of Temozolomide-Induced Hypermutation and Response to PD-1 Checkpoint Inhibitor in Recurrent Glioblastoma","volume":"4","author":"Daniel","year":"2022","journal-title":"Neuro Oncol. Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide Followed by Combination with Low-Dose Ipilimumab and Nivolumab in Patients with Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial","volume":"40","author":"Morano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain Immunology and Immunotherapy in Brain Tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-Cell Dysfunction in Glioblastoma: Applying a New Framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12967-025-06510-6","article-title":"Tertiary Lymphoid Structures in Gliomas: Impact on Tumour Immunity and Progression","volume":"23","author":"Chen","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-Genome and Multisector Exome Sequencing of Primary and Post-Treatment Glioblastoma Reveals Patterns of Tumor Evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/bjc.2015.297","article-title":"HLA Class I Is Most Tightly Linked to Levels of Tapasin Compared with Other Antigen-Processing Proteins in Glioblastoma","volume":"113","author":"Thuring","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-18-0599","article-title":"Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma","volume":"7","author":"Nejo","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41419-018-1183-8","article-title":"Long Noncoding RNA AC003092.1 Promotes Temozolomide Chemosensitivity through miR-195\/TFPI-2 Signaling Modulation in Glioblastoma","volume":"9","author":"Xu","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1535370220962715","article-title":"Identification of a Three-Long Non-Coding RNA Signature for Predicting Survival of Temozolomide-Treated Isocitrate Dehydrogenase Mutant Low-Grade Gliomas","volume":"246","author":"Li","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wu, X., Yang, L., Wang, J., Hao, Y., Wang, C., and Lu, Z. (2022). The Involvement of Long Non-Coding RNAs in Glioma: From Early Detection to Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.897754"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, Q., Zhuang, S., Chen, S., Wu, B., Zhou, Q., and Wang, W. (2025). Targeting the Dual miRNA\/BMP2 Network: LncRNA H19-Mediated Temozolomide Resistance Unveils Novel Therapeutic Strategies in Glioblastoma. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1577221"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.cmet.2013.09.013","article-title":"mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of C-Myc","volume":"18","author":"Masui","year":"2013","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16058","DOI":"10.1038\/s41598-019-52515-9","article-title":"Genomic Analysis of Primary and Recurrent Gliomas Reveals Clinical Outcome Related Molecular Features","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/noy034","article-title":"mTOR Inhibition in Glioblastoma: Requiem for a Dream?","volume":"20","author":"Babak","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2309290","DOI":"10.1002\/advs.202309290","article-title":"Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention","volume":"11","author":"Yue","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/s41388-023-02717-3","article-title":"TRIM25 Promotes Temozolomide Resistance in Glioma by Regulating Oxidative Stress and Ferroptotic Cell Death via the Ubiquitination of Keap1","volume":"42","author":"Wei","year":"2023","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12951-023-01801-w","article-title":"Exosome-Transmitted circCABIN1 Promotes Temozolomide Resistance in Glioblastoma via Sustaining ErbB Downstream Signaling","volume":"21","author":"Liu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e14386","DOI":"10.1111\/cns.14386","article-title":"Global Analysis of Iron Metabolism-Related Genes Identifies Potential Mechanisms of Gliomagenesis and Reveals Novel Targets","volume":"30","author":"Zhang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","article-title":"Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33670","DOI":"10.1038\/s41598-025-18255-9","article-title":"Assessment of Brain Penetration and Tumor Accumulation of Niraparib and Olaparib: Insights from Multimodal Imaging in Preclinical Models","volume":"15","author":"Groseclose","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102850","DOI":"10.1016\/j.ctrv.2024.102850","article-title":"PARP Inhibitors in Gliomas: Mechanisms of Action, Current Trends and Future Perspectives","volume":"131","author":"Cella","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","article-title":"ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1101\/gad.351084.123","article-title":"ATR Inhibition Induces Synthetic Lethality in Mismatch Repair-Deficient Cells and Augments Immunotherapy","volume":"37","author":"Wang","year":"2023","journal-title":"Genes Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1038\/s41598-022-09614-x","article-title":"Mismatch Repair Proteins Play a Role in ATR Activation upon Temozolomide Treatment in MGMT-Methylated Glioblastoma","volume":"12","author":"Ganesa","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.28551","article-title":"ATR Inhibition Using Gartisertib Enhances Cell Death and Synergises with Temozolomide and Radiation in Patient-Derived Glioblastoma Cell Lines","volume":"15","author":"Lozinski","year":"2024","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1021\/acs.jmedchem.4c02380","article-title":"Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"189482","DOI":"10.1016\/j.bbcan.2025.189482","article-title":"Revisiting CHK1 and WEE1 Kinases as Therapeutic Targets in Cancer","volume":"1880","author":"Kumar","year":"2025","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41467-023-36878-2","article-title":"Checkpoint Kinase 1\/2 Inhibition Potentiates Anti-Tumoral Immune Response and Sensitizes Gliomas to Immune Checkpoint Blockade","volume":"14","author":"Dmello","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"103093","DOI":"10.1016\/j.tice.2025.103093","article-title":"Combined Inhibition of WEE1 by AZD1775 Synergistically Enhances CX-5461 Mediated DNA Damage and Induces Cytotoxicity in Glioblastoma","volume":"97","author":"Cheng","year":"2025","journal-title":"Tissue Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12094-017-1743-x","article-title":"Acquired Temozolomide Resistance in Human Glioblastoma Cell Line U251 Is Caused by Mismatch Repair Deficiency and Can Be Overcome by Lomustine","volume":"20","author":"Stritzelberger","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1111\/cas.15141","article-title":"Lomustine and Nimustine Exert Efficient Antitumor Effects against Glioblastoma Models with Acquired Temozolomide Resistance","volume":"112","author":"Yamamuro","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bellamy, C., Hajal, C., Ligon, K.L., and Touat, M. (2025). Revisiting an Old Therapy for New, Promising Combinations: Biology and Perspectives of Lomustine in Glioma Treatment. Neuro Oncol., noaf192.","DOI":"10.1093\/neuonc\/noaf192"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cac2.12502","article-title":"Blockage of EGFR\/AKT and Mevalonate Pathways Synergize the Antitumor Effect of Temozolomide by Reprogramming Energy Metabolism in Glioblastoma","volume":"43","author":"Cui","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41420-025-02323-0","article-title":"The Emerging Roles of Aberrant Alternative Splicing in Glioma","volume":"11","author":"Mineo","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"eabn3471","DOI":"10.1126\/sciadv.abn3471","article-title":"Temozolomide-Induced Guanine Mutations Create Exploitable Vulnerabilities of Guanine-Rich DNA and RNA Regions in Drug-Resistant Gliomas","volume":"8","author":"Tiek","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1073\/pnas.1814060116","article-title":"Elevated Signature of a Gene Module Coexpressed with CDC20 Marks Genomic Instability in Glioma","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","first-page":"983","article-title":"The Selective Aurora-A Kinase Inhibitor MLN8237 (Alisertib) Potently Inhibits Proliferation of Glioblastoma Neurosphere Tumor Stem-like Cells and Potentiates the Effects of Temozolomide and Ionizing Radiation","volume":"73","author":"Hong","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.019","article-title":"Phase I Trial of Alisertib with Concurrent Fractionated Stereotactic Re-Irradiation for Recurrent High Grade Gliomas","volume":"132","author":"Song","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41591-025-03538-5","article-title":"Cerebrospinal Fluid Circulating Tumor DNA Profiling for Risk Stratification and Matched Treatment of Central Nervous System Metastases","volume":"31","author":"Zheng","year":"2025","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.annonc.2025.02.005","article-title":"ctDNA Detection in Cerebrospinal Fluid and Plasma and Mutational Concordance with the Primary Tumor in a Multicenter Prospective Study of Patients with Glioma","volume":"36","author":"Lorca","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the Mutational Signature of Homologous Recombination Deficiency in Clinical Samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101608","DOI":"10.1016\/j.xcrm.2024.101608","article-title":"Cancer Mutational Signatures Identification in Clinical Assays Using Neural Embedding-Based Representations","volume":"5","author":"Yaacov","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41698-025-00909-6","article-title":"Diagnostic and Prognostic Potential of Cell-Free RNAs in Cerebrospinal Fluid and Plasma for Brain Tumors","volume":"9","author":"Huang","year":"2025","journal-title":"npj Precis. Onc."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:02:44Z","timestamp":1766995364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cells15010057"],"URL":"https:\/\/doi.org\/10.3390\/cells15010057","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}